Alecensa 150 mg hard capsules, IMFINZI 50 mg/mL concentrate for solution for infusion.
BO42777
Phase 3 small_molecule active
Quick answer
Alecensa 150 mg hard capsules, IMFINZI 50 mg/mL concentrate for solution for infusion. for Non-Small Cell Lung Cancer (NSCLC) is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active